Leaflet: information for the user
Memantina Flas Combix 10 mg oral dispersible tablets EFG
memantine hydrochloride
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the leaflet:
Memantina Flas Combix contains the active ingredient memantine hydrochloride. It belongs to a group of medications known as anti-dementia medications.
Memory loss in Alzheimer's disease is due to an alteration in brain signals. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that participate in the transmission of important nerve signals in learning and memory. Memantine belongs to the group of medications called NMDA receptor antagonists. Memantine acts on these receptors, improving the transmission of nerve signals and memory.
Memantine is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do not take Memantina Flas Combix
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication:
In the above situations, treatment should be carefully monitored and your doctor should regularly reassess the clinical benefit of memantine.
If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
If you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction) or severe urinary tract infections, your doctor may need to adjust the dose of the medication.
The use of memantine with other medications such as amantadine (for the treatment of Parkinson's disease), ketamine (a medication generally used as an anesthetic), dextromethorphan (a medication for the treatment of cough), and other NMDA antagonists should be avoided.
Children and adolescents
The use of memantine is not recommended in children and adolescents under 18 years of age.
Other medications and Memantina Flas Combix
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
In particular, the administration of memantine may produce changes in the effects of the following medications, so your doctor may need to adjust the dose:
If you are hospitalized, inform your doctor that you are taking memantine.
Taking Memantina Flas Combix with food and drinks
You should inform your doctor if you have recently changed or plan to change your diet substantially (e.g., from a normal diet to a strict vegetarian diet), as your doctor may need to adjust the dose of the medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
The use of memantine is not recommended in pregnant women.
Breastfeeding
Women taking memantine should stop breastfeeding.
Driving and using machines
Your doctor will inform you if your illness allows you to drive and use machines safely.
Additionally, memantine may alter your reaction ability, so driving or operating machines may be inappropriate.
Memantina Flas Combix contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per oral dispersible tablet; it is essentially "sodium-free".
Memantina Flas Combix contains Red Allura AC
It may cause allergic reactions.
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended dose of memantine in adult and elderly patients is 20 mg administered once a day. To reduce the risk of side effects, this dose is gradually achieved by following the following daily treatment scheme:
Week 1 | Taking 5 mg once a day |
Week 2 | Taking 10 mg (one 10 mg tablet) once a day |
Week 3 | Taking 15 mg once a day |
Week 4 and subsequent weeks | Taking 20 mg (two 10 mg tablets or one 20 mg tablet) once a day |
The normal starting dose is one 5 mg tablet once a day for the first week. It is increased to one 10 mg tablet per day in the second week and to 15 mg once a day in the third week. From the fourth week onwards, the normal dose is two 10 mg tablets or one 20 mg tablet administered once a day.
Dosage for patients with renal impairment
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should periodically monitor your kidney function.
Administration
Memantine should be administered orally once a day. To get the most out of your medication, you should take it every day and at the same time. The tablets should be placed on the tongue and allowed to dissolve before swallowing them with or without water, as preferred by the patient. The tablets can be taken with or without food.
Duration of treatment
Continue taking memantine as long as it is beneficial for you. Your doctor should periodically evaluate the effects of your treatment.
Instructions for use
The oral dispersible tablets of memantina are fragile, so they should be handled with care.
Do not handle the tablets with wet hands, as they may break.
Place the tablet on your tongue. It will dissolve directly in the mouth, so it can be swallowed without water.
If you take more Memantina Flas Combix than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount administered.
If you forget to take Memantina Flas Combix
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Generally, side effects are classified as mild to moderate.
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known (frequency cannot be estimated from available data):
Alzheimer's disease has been associated with depression, suicidal ideation, and suicide. These events have been reported in patients treated with memantine.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the packaging and on the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Memantina Flas Combix
Appearance of the product and package contents
The oral dispersible tablets of Memantina Flas Combix are pale pink to pink mottled, round, flat, with beveled edges, engraved with "M10" on one face and smooth on the other. The diameter of the tablet is approximately 9 mm.
Memantina Flas Combix is available in blister packs of 112 oral dispersible tablets.
Marketing authorization holder
Laboratorios Combix, S.L.U.
C/ Badajoz 2. Edificio 2.
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
or
Netpharmalab Consulting Services S.L.
Carretera de Fuencarral 22
28108 Alcobendas, Madrid
Spain
or
Laboratori Fundacio DAU
C/De la letra C, 12-14,
Polígono Industrial de la Zona Franca,
08040 Barcelona,
Spain
or
Flavine Pharma France
3 Voie d’Allemagne
13127 Vitrolles
France
Date of the last revision of this leaflet: February 2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/